Tenaya Therapeutics (NASDAQ:TNYA) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research report sent to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $18.00 target price on the stock.

A number of other equities research analysts also recently issued reports on TNYA. Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reissued a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research note on Wednesday. Canaccord Genuity Group restated a “buy” rating and set a $16.00 price objective on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tenaya Therapeutics currently has an average rating of “Buy” and an average price target of $17.33.

Tenaya Therapeutics Stock Performance

Shares of TNYA opened at $1.23 on Wednesday. Tenaya Therapeutics has a fifty-two week low of $0.99 and a fifty-two week high of $7.01. The company has a market capitalization of $97.44 million, a PE ratio of -0.85 and a beta of 2.72. The stock has a fifty day moving average of $2.44 and a two-hundred day moving average of $2.72.

Tenaya Therapeutics (NASDAQ:TNYA) last released its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. As a group, equities research analysts forecast that Tenaya Therapeutics will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tenaya Therapeutics

Several large investors have recently made changes to their positions in the business. Synovus Financial Corp acquired a new position in shares of Tenaya Therapeutics during the 3rd quarter valued at $28,000. SG Americas Securities LLC purchased a new position in Tenaya Therapeutics in the third quarter valued at about $49,000. The Manufacturers Life Insurance Company lifted its stake in shares of Tenaya Therapeutics by 43.2% during the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after purchasing an additional 7,000 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Tenaya Therapeutics in the second quarter worth about $74,000. Finally, XTX Topco Ltd grew its stake in shares of Tenaya Therapeutics by 51.2% in the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after buying an additional 16,687 shares in the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.